NVP-CGM097-sulfate-CGM097-sulfate-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemENVP-CGM097 sulfateCat. No.: HY-15954BCAS No.: 1313367-56-4Synonyms: CGM097 sulfate分式: CHClNOS分量: 757.34作靶點(diǎn): MDM-2/p53作通路: Apoptosis儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) H2O : 140 mg/mL (

2、184.86 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 1.3204 mL 6.6021 mL 13.2041 mL5 mM 0.2641 mL 1.3204 mL 2.6408 mL10 mM 0.1320 mL 0.6602 mL 1.3204 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 NVP-CGM097是有效，選擇性的MDM2抑制劑；IC50值為1

3、.7 nM。IC50 & Target IC50 & Target: IC50: 1.70.1 nM (hMDM2) 1體外研究NVP-CGM097 binds to human MDM2 with an IC50 of 1.7 nM and shows high selectivity over MDM41/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE(IC50=2000 nM). NVP-CGM097 is about four times more potent than Nutlin-3a (IC50=8 nM). In additio

4、n,NVP-CGM097 shows no significant activity against Bcl-2:Bak, Bcl-2:Bad, Mcl-1:Bak, Mcl-1:NOXA,XIAP:BIR3, and c-IAP:BIR3 protein-protein interactions. NVP-CGM097 significantly inhibits the proliferationof cells expressing wild-type p53, while sparing the p53 null cells with a 35-58-fold difference.

5、NVP-CGM097is able to significantly redistribute wild-type p53 into the cell nucleus with an IC50 of 0.224 M, demonstratingits ability to inhibit the p53:MDM2 interaction in living cells. NVP-CGM097 significantly inhibits theproliferation of cells expressing wild-type p53, while sparing the p53 null

6、cells with a 35-58-fold difference.NVP-CGM097 inhibtis HCT116 (p53WT/WT) with IC50 of 454136 nM 1.體內(nèi)研究 NVP-CGM097 is able to inhibit the interaction between p53 and MDM2 and reactivate the p53 pathway in aMDM2-amplified SJSA-1 human tumor model, as judged by elevation of p21 mRNA levels, apharmacody

7、namic (PD) indicator for p53 activity. p21 mRNA levels are found to increase concomitantly withlevels of NVP-CGM097 in tumor-bearing rats dosed at 30 mg/kg. The PD response is biphasic and prolongedup to 24 h. Additional p53 target genes such as MDM2 and PUMA mRNA levels are assessed in the tumorsam

8、ples as well and showed a similar behavior. Daily treatment with NVP-CGM097 dose dependently andsignificantly inhibits SJSA-1 tumor growth in rats. It promotes stable disease at 20 mg/kg, which is associatedwith a plasma AUC0-24 of 163 Mh. After iv administration, the total blood clearance (CL) of N

9、VP-CGM097is 5 mL/min per kg for mouse, 7 mL/min per kg for rat, 3 mL/min per kg for dog, and 4 mL/min per kg formonkey. The apparent terminal half-life (t1/2) is long in rodents and monkey (6-12 h) but is comparativelylonger in dogs (20 h). After oral dosing, NVP-CGM097 is well absorbed with Tmax oc

10、curring between 1 and4.5 h in all species tested 1.PROTOCOLCell Assay 1 Two pairs of cell lines are used to assess NVP-CGM097 p53-dependent antiproliferative effects: (1) anisogenic pair of HCT116 cell lines either expressing wild-type p53 or knocked-out for the p53 gene and (2) anonisogenic pair of

11、 osteosarcoma cell lines either endogenously expressing wild-type p53 and amplified forMDM2 (SJSA-1 cells) or null for p53 (SAOS-2 cells) 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Female athymic rats bearing subcutaneous xenotransplants o

12、f SJSA-1 tumors (n=5-12) are treated at 5, 10,Administration 1 20, or 30 mg/kg or three times a week on Monday, Wednesday, and Friday (3qw M, W, F) at 30 or 70 mg/kgpo for 14 days. Plasma AUCs are determined at the end of the study. Positive numbers indicate thepercentage of tumor growth inhibition

13、(T/C); negative numbers indicate the percentage of tumor regression1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Holzer P, et al. Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 InhibitorUndergoing Phase 1 Clinical Trials in p53wt Tumors. J Med Chem. 2015 Aug 27;58(16):6348-58.McePdfHeight2/2 Master of Small Molecules 您邊的抑制劑師